article thumbnail

Top ten observations from 2022 in life sciences digital and analytics

McKinsey Public & Social Sector Insights

Life sciences companies are making progress in adopting and deploying digital and analytics. Insights on Life Sciences Pharmaceuticals DigitalBut they can go further and faster by heeding some lessons from the past few years.

article thumbnail

Resilience in life sciences: Emerging stronger from the downturn

McKinsey Public & Social Sector Insights

As the life sciences industry is tested by an uncertain economic environment, companies can focus not only on resilience but on positioning themselves to accelerate when coming out of the downturn. Insights on Life Sciences Medical products Pharmaceuticals

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Five ways that life science companies can build tech talent

McKinsey Public & Social Sector Insights

For life science companies to meet their digital ambitions, they must strengthen their technology skills. Insights on Life Sciences Health Care Pharmaceuticals DigitalIn a challenging market, emphasizing value propositions can attract first-rate talent.

article thumbnail

The case for cloud in life sciences

McKinsey

As cloud technology matures, life-sciences companies are generating new paths to business value beyond the cost efficiencies that cloud migrations typically target. Insights on Life Sciences Medical products Pharmaceuticals Cloud computing

article thumbnail

Against the odds: How life sciences companies excel in large transformations

McKinsey Public & Social Sector Insights

Life sciences companies pursuing a step change in performance have obtained mixed results. Insights on Life Sciences Pharmaceuticals Performance transformationAdhering to five principles can greatly improve the odds of a large transformation program succeeding.

article thumbnail

NetApp Applauded by Frost & Sullivan for Addressing Complex and Constantly Evolving Healthcare and Life Sciences Challenges with its Cloud Services

Frost & Sullivan Manufacturing

NetApp brings clear value for payers, healthcare providers, and life sciences companies while ensuring the best outcomes through its customer-centered and data-centric approach. Best Practice Awards Healthcare & Life Sciences Best Practices News Press Releases

article thumbnail

Middle East 2023 Top 5 Trends to Watch in Healthcare & Life Sciences Industry

Frost & Sullivan Manufacturing

Middle East 2023 Top 5 Trends to Watch in Healthcare & Life Sciences Industry. The post Middle East 2023 Top 5 Trends to Watch in Healthcare & Life Sciences Industry appeared first on Frost & Sullivan.

article thumbnail

Top 10 Growth Opportunities in the Healthcare & Life Sciences Industry

Frost & Sullivan

31, 2022 – The post COVID-19 pandemic recovery and other geopolitical events in 2021 has left the healthcare & life sciences industry in a remarkable position to be ready for 2022 and beyond. San Antonio, TX, – Jan.

article thumbnail

LHS Expert Insights: ESG Issues for Life Science Innovators

LaVoie Health Science Blog

Interviews with our senior practice managers about issues of important to life science innovators. As investments into sustainable companies and funds have surged to new highs, how can biotech and life science companies best position themselves with this burgeoning group of investors.

article thumbnail

Life Sciences’ Contribution to the US Digital Therapeutics Market to Grow the Fastest amongst all End Users

Frost & Sullivan

As life sciences companies aim to enhance patients’ treatment experiences and find new biomarkers that aid drug discovery, DTx companies diversify their pipelines by adding new indications, addressing unmet needs.

article thumbnail

Life Sciences’ Contribution to the US Digital Therapeutics Market to Grow the Fastest amongst all End Users

Frost & Sullivan

As life sciences companies aim to enhance patients’ treatment experiences and find new biomarkers that aid drug discovery, DTx companies diversify their pipelines by adding new indications, addressing unmet needs.

article thumbnail

Women in healthcare and life sciences: The ongoing stress of COVID-19

McKinsey

The healthcare sector is examining how to better hire and promote women to the highest levels. Insights on Healthcare Systems & Services Health care providers Pharmaceuticals

article thumbnail

ZAGENO Applauded by Frost & Sullivan for Simplifying the Supply Chain for Life Science Research with Its e-Commerce Platform

Frost & Sullivan Manufacturing

July 19, 2022- Recently, Frost & Sullivan assessed the life sciences e-commerce industry, and, based on its findings, recognizes ZAGENO with the 2022 Customer Value Leadership Award. Best Practice Awards Healthcare & Life Sciences Best Practices News Press Releases

article thumbnail

ArisGlobal Lauded by Frost & Sullivan for Enabling Life Sciences Companies to Accelerate R&D with Its LifeSphere® Platform

Frost & Sullivan

LifeSphere supports hundreds of global life sciences companies to accelerate development, maintain compliance, and streamline collaboration between cross-functional teams. Best Practice Awards Healthcare & Life Sciences Best Practices News Press Releases

article thumbnail

How Daiichi Sankyo Europe drives growth with digital and analytics

McKinsey Public & Social Sector Insights

Digital and analytics can markedly improve life sciences companies’ engagement with customers. Insights on Life Sciences Pharmaceuticals Digital strategy and organization

article thumbnail

8 Growth Opportunities in the Healthcare and Life Sciences Industry to Watch Out for in 2021

Frost & Sullivan

To help companies identify new avenues for top-line growth and plan for a more fruitful 2021, Frost & Sullivan’s team of industry experts have compiled a complimentary insight: Top 8 Growth Opportunities in the Healthcare and Life Sciences Industry for 2021 – What You Need to Know Now.

article thumbnail

Capgemini Applauded by Frost & Sullivan for Enabling Businesses in the Life Sciences Industry to Transform and Manage Their Processes with Its End-to-end Digital Transformation and Technology Services

Frost & Sullivan

January 11, 2022 – Frost & Sullivan analyzed global digital transformation services in the life sciences industry and, based on its findings, recognizes Capgemin i with the 2021 Global Company of the Year Award for digital transformation services within life sciences.

article thumbnail

The health benefits and business potential of digital therapeutics

McKinsey Public & Social Sector Insights

Insights on Life Sciences PharmaceuticalsDigital-native start-ups and healthcare incumbents can both play important roles in building and scaling digital therapeutics to improve the management of chronic health conditions.

article thumbnail

Real-world data quality: What are the opportunities and challenges?

McKinsey Public & Social Sector Insights

Insights on Life Sciences PharmaceuticalsGrowth in the availability and variety of real-world data, including nonhealth sources of data, opens up new opportunities, as well as challenges, in their application to real-world evidence and improving health outcomes.

article thumbnail

Steadfast but nimble: CEO Christi Shaw on cancer treatment’s cutting edge

McKinsey Public & Social Sector Insights

Insights on Life Sciences Oncology/Cancer InnovationKite’s CEO discusses the company’s CAR T-cell therapies and what it means to put patients first.

article thumbnail

AI for medtech commercial growth: Five missteps to avoid

McKinsey Public & Social Sector Insights

Insights on Life Sciences Medical products AnalyticsMedtech companies are looking to AI and advanced analytics to help retool their commercial models to meet customers’ evolving expectations—but common misunderstandings can delay progress.

article thumbnail

Digital health: An opportunity to advance health equity

McKinsey

Insights on Life Sciences Health care reformDigital health solutions have the potential to make healthcare more equitable. Here’s how innovators can deliver on that promise.

article thumbnail

Health equity: A framework for the epidemiology of care

McKinsey

Pharmaceutical and life sciences companies can unlock new opportunities, help underserved patients, and build a cycle of trust. Insights on Life Sciences Health care reform Pharmaceuticals

article thumbnail

How sterile pharma manufacturers can grow capacity without capital investment

McKinsey Public & Social Sector Insights

Insights on Life Sciences PharmaceuticalsThe world will need more sterile products than manufacturers have or can build capacity for. But they can create capacity and take market share by running higher volumes through their existing lines.

article thumbnail

Reimagining the future of biopharma manufacturing

McKinsey Public & Social Sector Insights

Insights on Life Sciences BiotechnologyLeveraging digital and analytics advances can unlock significant value for biopharma companies through gains in quality, speed, agility, and resilience.

article thumbnail

What are the biotech investment themes that will shape the industry?

McKinsey

Insights on Life Sciences BiotechnologyFrom 2019 to 2021, venture capitalists plowed $35 billion into biotech companies with advanced platform technologies that could transform the industry.

Biotech 104
article thumbnail

Europe’s Bio Revolution: Biological innovations for complex problems

McKinsey Public & Social Sector Insights

Advances in biological science could help the world overcome its most pressing challenges in health and sustainability. Insights on Life Sciences Health care services Pharmaceuticals Europe Climate changeEurope’s Bio Revolution could translate scientific strengths into impact.

article thumbnail

The Helix report: Is biopharma wired for future success?

McKinsey Public & Social Sector Insights

Insights on Life Sciences Health Care PharmaceuticalsThe biopharmaceutical industry has made remarkable achievements in the past decade, but is it equipped to leap still further ahead in the coming one? Company leaders’ answers to nine questions could prove decisive.

article thumbnail

A new operating model for pharma: How the pandemic has influenced priorities

McKinsey

Insights on Life Sciences PharmaceuticalsThe COVID-19 pandemic has prompted pharma companies to rethink their organizational strategies. A survey of executives suggests where value might lie.

article thumbnail

Out of the shadows: A brighter future for pharma technical development

McKinsey Public & Social Sector Insights

Insights on Life Sciences Pharmaceuticals InnovationThe sometimes-overlooked function of chemistry, manufacturing, and controls (CMC) has a rare opportunity to reimagine its role and find innovative ways to improve and accelerate drug development.

article thumbnail

The rise of digital marketing in medtech

McKinsey

Insights on Life Sciences Medical products Digital marketing AnalyticsDigital marketing offers medtech companies powerful ways to personalize engagement with healthcare professionals and respond to their changing needs.

article thumbnail

Building pharma pipelines using a socioeconomic lens

McKinsey

Harnessing advances in science and technology can deliver transformative therapies faster while reducing the socioeconomic burden of disease. Insights on Life Sciences Biotechnology Innovation

article thumbnail

Developing a customer-centric approach to rare conditions

McKinsey Public & Social Sector Insights

Insights on Life Sciences Pharmaceuticals Medical productsRoche Pharmaceuticals’ approach to rare conditions highlights industry efforts to make a difference for patients, their caregivers, and healthcare professionals.

article thumbnail

Advancing real-world evidence for pharmaceutical companies in Japan

McKinsey

Insights on Life Sciences Pharmaceuticals JapanPharma companies in Japan have an opportunity to obtain value from real-world evidence using advanced analytics and to better ensure patient outcomes.

article thumbnail

How the European biotech sector can navigate turbulent times

McKinsey Public & Social Sector Insights

Insights on Life Sciences BiotechnologyThe recent market downturn has affected biotechs worldwide. But the fundamentals are still strong in Europe, where companies have an opportunity to lead the next phase of bioscience innovation.

Biotech 82
article thumbnail

Generating real-world evidence at scale using advanced analytics

McKinsey

Insights on Life Sciences Pharmaceuticals AnalyticsAs pharma companies apply advanced analytics to generate new types of evidence, how do they decide which use cases to target and how to scale them up across the business?

article thumbnail

The UK biotech sector: The path to global leadership

McKinsey

The United Kingdom is Europe’s leading biotech hub in breakthrough life-sciences start-ups. Insights on Life Sciences Pharmaceuticals Medical products United KingdomHow is this hub maturing relative to its global peers, and what lies ahead on the road to sustainable scale?

Biotech 106
article thumbnail

Vision 2028: How China could impact the global biopharma industry

McKinsey Public & Social Sector Insights

Insights on Life Sciences PharmaceuticalsChina-originated biopharmas will likely have greater influence on the industry by 2028, but regulatory developments and the quality of partnerships will determine how the industry grows.

article thumbnail

AI in biopharma research: A time to focus and scale

McKinsey Public & Social Sector Insights

Insights on Life Sciences PharmaceuticalsBy focusing on specific scientific and operational pain points and fully integrating AI into research workflows, biopharma companies can deliver greater patient impact and significant value.

article thumbnail

Better data for better therapies: The case for building health data platforms

McKinsey

Insights on Life Sciences Health care services Health Care PharmaceuticalsHealth data platforms that participants trust could bring an end to today’s reductionist approach to drug development, revolutionizing our understanding of disease.